Download by
Scanning QR Code
No Stock Yet
Minsheng Securities: The size of the optoelectronic medical and aesthetic market continues to rise, and the advantages of segmentation are gradually being highlighted
The Zhitong Finance App learned that Minsheng Securities released a research report saying that the optoelectronic medical and aesthetic program refers to medical and aesthetic devices as energy sources that act on the skin treatment technology through forms of energy such as lasers, radiofrequency, and ultrasound. As awareness of light medicine and aesthetics increases, the size of the optoelectronic medical and aesthetic market continues to rise. Domestic enterprises are mostly involved in mergers and acquisitions in the optoelectronics market, and their advantages in segmentation are gradually becoming prominent. 1) FuRui Medical Technology (01696): The merger and acquisition of Feyton lays out the market and seizes pain points to provide services. 2) Huadong Pharmaceutical (000963.SZ): Acquisition+participation in the optoelectronics market, with a rich product matrix. 3) Haohai Biotechnology (06826)
Huadong Pharmaceutical (000963.SZ): Will actively promote the introduction of more high-end innovative medical and aesthetic products from abroad into the Hainan Boao Lecheng International Medical Tourism Pilot Zone
Gelonghui, March 3 丨 Huadong Pharmaceutical (000963.SZ) was recently surveyed by an agency, saying, “If consumers go to Hong Kong to get injections for young girls, how is this revenue calculated?” Time said that the sales promotion of the company's Ellansé products in Hong Kong is represented by a third party dealer, so the revenue of regular Ellansé products in the Hong Kong region belongs to Sinclair, the company's wholly-owned subsidiary in the UK. Also, as for “what products will the company Medical and Aesthetic be listed domestically in the next 2-3 years?” Shi said that this year, the company introduced the Irish EMA's facial skin care device Préime D
Huadong Pharmaceutical: Liraglutide injections for diabetes indications and those for obesity or overweight are all expected to be approved for marketing this year
Huadong Pharmaceutical (000963): “Medical Aesthetics+Microelectronics” two-wheel drive growth has reached a new level
Core view: The pharmaceutical industry is stabilizing, and the development of medical aesthetics and industrial microorganisms has reached a new level. The company's performance in the pharmaceutical industry sector has been under pressure in the past few years due to centralized drug procurement and medical insurance negotiations. At present, the company's procurement pressure in the pharmaceutical industry is gradually decreasing, and it has returned to a normal growth channel. The medical, aesthetic and industrial microbiological fields are in a period of rapid development, which is expected to contribute greatly to performance flexibility in the next 2-3 years. Net interest rates for overseas medical and aesthetic businesses are expected to rise rapidly, contributing to greater profit elasticity to the sector. Sinclair and HighTech are the main components of the company's overseas medical and aesthetic business, and the net interest rates in 2019 were all
Huadong Pharmaceutical (000963.SZ): Sinclair is also expected to achieve good growth this year
Glonhui Feb. 20 丨 Huadong Pharmaceutical (000963.SZ) on February 15, 2023, 14:30-16:00; February 16 11:00-11:40 and 14:00-15:00, said that Sinclair's current medical and aesthetic revenue mainly comes from core injectable products such as Ellansé®, the new high-end hyaluronic acid in the MAILI series, Lanluma® collagen stimulants, etc., and its subsidiary HighTech's Cooltech Define, Viora Company Production of energy source equipment such as V series
Huadong Pharmaceutical (000963.SZ): PréimedermaFacial, a facial skin care device introduced by the Irish EMA company this year, is expected to be marketed in China
Glonhui, Feb. 20, 丨 Huadong Pharmaceutical (000963.SZ) was surveyed on-site by the agency at 14:30-16:00 on February 15, 2023; 11:00-11:40 and 14:00-15:00 on February 16, it said that Cool Snow Glacial Spa® officially entered the domestic market in March last year. Affected by the epidemic and supply chain delivery volume factors, the current revenue share is not high. The company's relevant teams are also actively developing their business this year, and it is expected that the product will perform better this year. This year, the company introduced facial skin care equipment from EMA Ireland
Huadong Pharmaceutical (000963.SZ): Maggie Health has accumulated a number of intended customers and orders
Glonghui, Feb. 20, 丨 Huadong Pharmaceutical (000963.SZ) was surveyed on-site by the agency at 14:30-16:00 on February 15, 2023; 11:00-11:40 and 14:00-15:00 on February 16, saying that Maggie Health has already accumulated a number of intended customers and orders, which will lay a good foundation for development after it is officially put into operation in the second half of this year. Huaren Technology's main business areas are small nucleic acid drugs and nucleoside raw materials for diagnostic reagents. As the global epidemic situation slows down, the growth rate of the diagnostic reagent business will decline compared to before. However, in the field of nucleoside raw materials for small nucleic acid drugs
Huadong Pharmaceutical (000963.SZ): ELAHERE™, the world's first ADC drug for treating platinum-resistant ovarian cancer, plans to submit a BLA application to NMPA in the second half of the year
Gelonghui, Feb. 20, 丨 Huadong Pharmaceutical (000963.SZ) said on February 15, 2023 at 14:30-16:00; on February 16, 11:00-11:40 and 14:00-15:00, in response to institutional field research, that on November 15, 2022, ImmunoGen, an American partner of Huadong Pharmaceutical, announced to the outside world that its first-in-class (first-in-class) ADC drug for the treatment of platinum-resistant ovarian cancer is mirvetuximelaHERE™ (mirvetuximab) soravtansine-gynx,
Huadong Pharmaceutical (000963.SZ): Important varieties of diabetes pipelines are expected to continue to grow rapidly this year
Glonhui, Feb. 20, 丨 Huadong Pharmaceutical (000963.SZ) said on February 15, 2023 at 14:30-16:00; on February 16, 11:00-11:40 and 14:00-15:00 during on-site research by the agency, that the company's Belling series and acarbose series products are expected to grow steadily this year, an improvement over the previous two years. The company's important varieties of diabetes pipelines are also expected to continue to grow at a relatively rapid pace this year. Both indications of liraglutide injections are expected to be approved for marketing this year, bringing new increases. Immunosuppressant products have continued to grow steadily, and the cardiovascular sector is core
Huadong Pharmaceutical (000963.SZ): Looking at the whole, the peak period of influence of collection on the company is over
Glonghui, Feb. 20, 丨 Huadong Pharmaceutical (000963.SZ) was surveyed on-site by the agency at 14:30-16:00 on February 15, 2023; 11:00-11:40 and 14:00-15:00 on February 16, said that last year, the company's products such as temecophenol ester capsules, pioglitazone hydrochloride tablets, and ornidazole tablets participated and successfully won the bid for the seventh batch of centralized national drug procurement. Implementation has now begun in various provinces and cities. As the country continues to promote the normalization of centralized drug procurement, some of the company's generic drugs will still face the impact of national, provincial and municipal alliances in the future. But from the whole
Loading...
No Stock Yet